September/October 2021
IP Litigator
By Brandon T. Andersen; J. Derek McCorquindale; Daniel C. Cooley
In recent days, increased attention has been given to government funding on the national and state level, for example through investment in our country’s infrastructure. Some of those resources may be directed to research and development, spurring innovation in the private sector. The parties who accept government contracts or other federal grants should consider how such funds could lead to the development of patentable inventions and how patents obtained on those inventions may ultimately be enforced. While some may be familiar with securing and enforcing patents directed to inventions developed in-part or in-whole using federal resources, many will soon encounter this scenario for the first time. This article is part of a two-part series addressing the acquisition and litigation of patent rights directed to inventions developed with the support of government grants or contracts.
In this article, we provide a brief overview of the Bayh–Dole Act, which controls the allocation of intellectual property rights in inventions developed using federal funding, and its implications on both obtaining and retaining enforceable patents. In the second article, we will explore the considerations and requirements when bringing or facing an enforcement action based on those patents.
Read "The Allocation of Patent Rights in Government Funded Inventions"
Reprinted with permission from the IP Litigator, published by Wolters Kluwer. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.